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Background
Allergic reactions to peach are highly prevalent in the
Mediterranean area with persistent and potentially life
threatening symptoms. We aimed to develop a save and
efficient immunotherapeutics for treatment of peach
allergy by targeting the major allergen Pru p 3.
Methods
We deployed an in-silico mutagenesis approach to design
a fold variant of recombinant Pru p 3. Four stability hot
spot residues were identified and proline was predicted
as the most effective replacement amino acid. Pru p 3 C1
was produced in E.coli using a pET-based expression sys-
tem. After refolding and purification by cation exchange
chromatography, the protein was characterized by redu-
cing and non-reducing gel electrophoresis, circular
dichroism spectroscopy, size exclusion chromatography,
dynamic light scattering and mass spectrometry (MS).
An accelerated stability test was performed by storing
the protein up to 6 month at temperatures ranging from
-70°C to +40°C.The IgE binding capacity of Pru p 3 C1
and WT Pru p 3 was tested in ELISA using sera from
peach allergic patients. Different adjuvants and adsorp-
tion conditions were evaluated for use in a mouse model.
Mice were s.c. immunized with Pru p 3 C1 and WT Pru
p 3 and sera were analyzed for IgG reactivity.
Results
Recombinant Pru p 3 C1 was produced with a yield of 15
mg/l expression volume. The purity and identity of the
protein was confirmed in gel electrophoresis and MS. In
size exclusion chromatography and dynamic light scatter-
ing the protein showed to be >90% monomeric. Circular
dichroism spectroscopy showed that the protein is predo-
minantly in an unfolded state. Thermal denaturation led
to a shift of the spectrum which reverted to the initial
curve after renaturation. After six month of storage Pru p
3 C1 demonstrated high stability and no aggregation or
degradation behavior at temperatures ranging from -70°C
to +4°C. In ELISA, the IgE binding capacity of Pru p 3 C1
was reduced by 89% compared to WT Pru p 3. In vivo
models showed that the use of aluminum phosphate as
adjuvant is superior over aluminum hydroxide. Immuni-
zation with Pru p 3 C1 induced a humoral immune
response in all animals and triggered cross-reactive IgG1
antibodies in 50% of mouse sera.
Conclusion
Pru p 3 C1 shows high stability, strongly reduced IgE bind-
ing capacity and immunogenicity. Therefore, the molecule
is a very promising candidate for treatment of peach allergy.
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